Navigation Links
Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
Date:9/26/2011

TAMPA, Fla., Sept. 26, 2011 /PRNewswire/ -- Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost In the study, non-preserved latanoprost was compared to Xalatan® (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.  Non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan.  In addition, non-preserved latanoprost was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.  Xalatan is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; it was approved by the US Food and Drug Administration for use in 1996.  Xalatan is the registered trademark of Pfizer, Inc. 

Clermont obtained the US rights to non-preserved latanoprost from Laboratoires Thea S.A.S, an ophthalmic pharmaceutical company based in France.  Laboratoires Thea recently filed an application for European marketing authorization with the EMEA. 

Based on these positive results, Clermont intends to file a New Drug Application with the US FDA in the fourth quarter of 2011.  Clermont plans to begin discussions with potential marketing partners in the near future.   

About Open-Angle Glaucoma

Open-angle glaucoma is the most common type of glaucoma and the leading cause of blindness among adults in the US – mostly because it can progress gradually and go unnoticed for years.  An increase in eye pressure occurs slowly over time.  This pressure pushes on the optic nerve and the retina at the back of the eye.  The cause of open-angle glaucoma is unknown, but it tends to be hereditary, with people of African descent at particularly high risk. 

About Clermont Pharmaceuticals

Clermont Pharmaceuticals, Inc. is a privately held Florida based ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma. 

About Laboratoires Thea

Laboratoires Thea was founded in 1994 and is managed by Henri and Jean-Frederic Chibret. Laboratoires Thea is a 350 MUSD ophthalmic pharmaceutical company and is the leading independent ophthalmic group in Europe and is committed to the development and marketing of innovative ophthalmic drugs, medical devices, and nutraceuticals.


'/>"/>
SOURCE Clermont Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
2. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
3. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
9. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
10. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
11. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Ahead of today,s trading session, Stock-Callers.com draws investors, ... at the close: Kite Pharma Inc. (NASDAQ: KITE ), ... and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to ... Friday, January 20 th , 2017, down on the day by ... stocks now at: ...
(Date:1/23/2017)... , 23 janvier 2017  ResMed (NYSE : RMD), ... , Floride) ont annoncé aujourd,hui qu,ils se sont mis ... existants entre les parties. BMC et 3B seront autorisés ... de droits à ResMed, et ResMed effectuera le paiement ... pour clore le litige de Floride entre les deux ...
(Date:1/23/2017)... weeks remain until legal experts and senior industry leaders involved in supply ... to discuss the flow of pharmaceutical products post Brexit at the ... . In the run up to the show, SMi Group ... in the event download centre . ... Some of those confirmed include: EMA, Aeterna ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... Old School Labs™, makers of the wildly popular all-natural sports supplements based ... its growing team of brand ambassadors. The Olympia top finisher and former Big 12 ... year was able to turn professional, participating in the 2013 NPC USA Championships in ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... Zifam Pinnacle, ... across the world, recently met with big-name retail buyers at the January ECRM Trade ... of efficacy and uses the utmost safety standards in all of its creations to ...
(Date:1/21/2017)... Viejo, California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set ... one subject to another subject in a scene," said Christina Austin - CEO of Pixel ... a given scene. Easily create the illusion of a DSLR racking focus from one ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
Breaking Medicine News(10 mins):